Mirna is a veterinary diagnostics company that specializes in the development of veterinary disease testing technology.
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Buffalo Grove, Illinois, focused on developing and commercializing innovative treatments for gastrointestinal diseases. Established in 2018 and launched in 2019, the company is advancing its lead drug candidate, vonoprazan, a potassium-competitive acid blocker (P-CAB) that effectively inhibits acid secretion in the stomach. Vonoprazan is currently undergoing Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease and is also being studied in combination with antibiotics for the treatment of Helicobacter pylori infection. The company aims to address significant unmet medical needs in patients suffering from acid-related disorders and has assembled a team of experts in the gastrointestinal and pharmaceutical fields to drive its development efforts.
Hansa Biopharma is a biopharmaceutical company focused on developing immunomodulatory treatments for individuals with rare immunological diseases. The company aims to create innovative and life-altering therapies that address critical unmet medical needs in areas such as transplantation, autoimmune diseases, gene therapy, and oncology. Hansa Biopharma employs a proprietary antibody-cleaving enzyme technology platform to target disease-causing antibodies. Its lead product candidate, imlifidase, is designed to facilitate kidney transplantation in sensitized patients and is being explored for potential applications in other organ transplants and acute autoimmune conditions. The company operates primarily in Sweden, other European countries, and the United States, generating most of its revenue from product sales.
Lexitas Pharma Services is a full-service clinical research organization (CRO) focused on supporting pharmaceutical and biotechnology companies in the management of ophthalmic clinical trials. The company provides a comprehensive range of services, including clinical operations, study design, content development, monitoring, medical oversight, and site relations. By leveraging its expertise, Lexitas Pharma facilitates the efficient execution of various phases of clinical trials, thereby enabling its clients to advance their ophthalmic research and development initiatives.
TARGAN is a bio-systems company dedicated to enhancing animal health and productivity in the poultry, livestock, and aquaculture sectors. It is developing an innovative vaccination system that aims to replace traditional mass spray methods with a more precise approach, ensuring that every newly hatched chick receives the appropriate vaccine. This technology not only aims to improve immunization rates but also enhances the natural immune response to diseases, leading to better overall flock health. By increasing vaccination accuracy and consistency, TARGAN's solution helps reduce reliance on antibiotics, contributing to cleaner and healthier livestock. The company's focus on improving animal well-being and operational efficiency positions it as a leader in the field of animal production.
Covenant Animal Health Partners focuses on the development and registration of revenue-ready animal health products. The company aims to meet critical market needs for both production and companion animals by advancing new assets into the portfolios of industry partners. By providing innovative solutions, Covenant assists animal health manufacturers and distributors in enhancing their product offerings.
Private Equity Round in 2021
Dermavant Sciences is a biotechnology company focused on dermatology.
Private Equity Round in 2021
Argenta is a contract research organization (CRO) and contract manufacturing organization (CMO) specializing in animal health.
Private Equity Round in 2021
Aceragen is a clinical-stage biopharmaceutical company focused on developing innovative therapeutic treatments for rare and ultra-rare diseases. The company is engaged in the discovery, development, and commercialization of therapeutics, particularly in oncology and rare diseases. Aceragen emphasizes late-stage programs rooted in established biological principles, aiming to create inventive solutions that address the unmet medical needs of patients affected by these conditions.
Cerevel Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuroscience diseases. Established in 2018 and based in Cambridge, Massachusetts, the company is advancing a diversified pipeline that includes several clinical-stage investigational therapies targeting conditions such as schizophrenia, epilepsy, Parkinson's disease, and substance use disorder. Notable products in development include CVL-231, a positive allosteric modulator currently in Phase Ib trials for schizophrenia, and CVL-865, also a positive allosteric modulator, which is in Phase II trials for drug-resistant focal onset seizures. Additionally, Tavapadon, a selective dopamine D1/D5 partial agonist, is in a Phase III program for Parkinson's disease, while CVL-936, a selective dopamine D3-preferring antagonist, is undergoing Phase I trials for substance use disorder. The company is also engaged in preclinical research aiming to address various neuroscience indications, leveraging expertise in neurocircuitry and receptor selectivity.
Pro-ficiency specializes in tech-enabled training and compliance solutions tailored for clinical trials. The company offers a comprehensive platform that includes virtual training simulators and tools designed for training and compliance monitoring. Its services encompass original content creation and analytics, providing clinical trial investigators and site staff with resources to enhance their training experience. By delivering real-time data and predictive analytics, Pro-ficiency enables sponsors to anticipate and mitigate study errors and protocol violations. This approach ultimately aims to reduce the time, cost, and risks associated with clinical trials, enhancing overall efficiency in the process.
CoreRx, Inc. is a contract development manufacturing organization (CDMO) based in Clearwater, Florida, that supports pharmaceutical and biotechnology companies in the development, manufacturing, and testing of various dosage forms, including solid, liquid, and semi-solid medications. Founded in 2006, the company offers a comprehensive range of services, including pre-formulation evaluations, formulation and development for tablets and other forms, as well as manufacturing and packaging of medications such as capsules, gels, creams, and ointments. CoreRx emphasizes rigorous quality systems and extensive instrumentation to deliver timely results, helping clients accelerate product development while managing costs effectively.
Mileutis LTD is a biopharmaceutical company based in Ness Ziona, Israel, founded in 2004. It specializes in the discovery, development, and commercialization of biologically sourced therapies aimed at improving both animal and human health. The company offers products such as Imilac, an intramammary solution designed for use at the beginning of the dry period to manage mastitis and enhance milk production, and Milac, which treats intramammary infections during lactation. Mileutis focuses on developing natural and novel peptides, which hold significant potential for addressing chronic and infectious diseases while reducing the reliance on antibiotics in both veterinary and human medicine. Its innovations also enhance veterinary dairy management by increasing productivity, thereby benefiting overall health management strategies.
Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders.
InformedDNA specializes in genetics benefits management services, focusing on enhancing healthcare spending and patient care through access to clinical and scientific genomics expertise. The company connects genetic counselors with patients, providing essential services such as policy development, prior authorization for genetic testing, payment integrity claims edits, utilization analytics, and lab network strategies. By leveraging a team of board-certified genetics specialists, InformedDNA aims to guide patients and clinicians in the effective use of genetics and gene-based treatments, ultimately improving medical outcomes. Their approach combines the latest genomics insights with practical clinical experience, allowing health organizations, providers, and pharmaceutical companies to make informed decisions that optimize clinical practices and manage costs. With a strong commitment to patient care and a personalized touch, InformedDNA serves as a trusted resource in the evolving field of genomics medicine.
Private Equity Round in 2019
Nevakar Inc. is a pharmaceutical company based in Bridgewater, New Jersey, specializing in the development of innovative ophthalmic and injectable products. Founded in 2015, the company aims to create enhanced formulations of existing FDA-approved molecules to meet unmet clinical and commercial needs. Nevakar's efforts are underpinned by a robust research and development infrastructure situated in the New Jersey Center of Excellence, complemented by a seasoned management and leadership team. Through intensive R&D and clinical initiatives, Nevakar is committed to advancing healthcare solutions in its specialized fields.
Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders.
Mesoblast Limited is a biopharmaceutical company focused on developing and commercializing allogeneic cellular medicines aimed at treating complex diseases that are resistant to conventional therapies. Utilizing its proprietary Mesenchymal Precursor Cell (MPC) technology, the company targets a range of conditions, including cardiovascular disorders, orthopedic spine issues, inflammatory diseases, and various cancers. Key products in development include MSC-100-IV for steroid refractory acute graft versus host disease, MPC-150-IM for advanced heart failure, and MPC-06-ID for chronic low back pain. Additionally, Mesoblast is advancing MPC-300-IV, currently in Phase II trials, for the treatment of biologic refractory rheumatoid arthritis and diabetic kidney diseases. The company operates in several countries, including the United States, Australia, and the United Kingdom, and has established strategic partnerships to enhance its product offerings in specific markets. Founded in 2004 and headquartered in Melbourne, Australia, Mesoblast is committed to leveraging its innovative technology to address unmet medical needs.
Azurity Pharmaceuticals is a pharmaceutical company focused on developing and marketing drug products to meet the needs of patients with specific medical conditions. The company specializes in creating oral liquid medications, which cater to individuals such as children and elderly patients who may have difficulty swallowing traditional pills or tablets. Its product portfolio includes treatments for conditions like attention deficit hyperactivity disorder (ADHD), hypertension, and congestive heart failure, as well as antimicrobial treatments and mouthwashes. By providing innovative alternatives to traditionally compounded medications, Azurity Pharmaceuticals aims to improve patient care and address unmet medical needs.
Viamet Pharmaceuticals discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileâ„¢ Technology. Viamet's disruptive Metallophileâ„¢ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allows them to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors.
Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women's health and endocrine diseases. Its lead product, relugolix, is an oral, once-daily gonadotropin-releasing hormone receptor antagonist designed to treat heavy menstrual bleeding associated with uterine fibroids, endometriosis-related pain, and advanced prostate cancer. The company is also advancing MVT-602, an oligopeptide kisspeptin agonist that has completed a Phase 2a study aimed at addressing female infertility in assisted reproduction. Myovant Sciences was established in 2016 and is headquartered in Brisbane, California. It collaborates with Pfizer to develop and commercialize relugolix across oncology and women's health.
PreCision Dermatology is a fully-integrated dermatology company focused on delivering innovative therapies that enhance skin care for both doctors and patients. The company specializes in developing dermatological products, including a drug delivery platform designed to improve the efficacy of active ingredients while minimizing side effects and enhancing the natural skin barrier. This technology enables the treatment of various dermatological conditions, such as atopic dermatitis, acne, and rosacea. PreCision Dermatology is experiencing rapid growth through a combination of internal innovation, acquisitions, in-licensing, and co-marketing strategies, positioning itself as a key player in the skincare industry.
Revance Therapeutics is a biotechnology company that focuses on developing, manufacturing, and commercializing neuromodulators for aesthetic and therapeutic applications. Its primary product, DaxibotulinumtoxinA for injection (DAXI), is undergoing various clinical trials for treating conditions such as glabellar lines, cervical dystonia, adult upper limb spasticity, and plantar fasciitis, while also being explored for chronic migraine treatment. Additionally, Revance is developing topical formulations of DAXI and a biosimilar to BOTOX. The company has established collaborations for the development and commercialization of these products. Revance also offers a portfolio of aesthetic products, including the RHA Collection of dermal fillers and the HintMD platform. Founded in 1999 and headquartered in Newark, California, Revance Therapeutics was previously known as Essentia Biosystems.
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.
Revance Therapeutics is a biotechnology company that focuses on developing, manufacturing, and commercializing neuromodulators for aesthetic and therapeutic applications. Its primary product, DaxibotulinumtoxinA for injection (DAXI), is undergoing various clinical trials for treating conditions such as glabellar lines, cervical dystonia, adult upper limb spasticity, and plantar fasciitis, while also being explored for chronic migraine treatment. Additionally, Revance is developing topical formulations of DAXI and a biosimilar to BOTOX. The company has established collaborations for the development and commercialization of these products. Revance also offers a portfolio of aesthetic products, including the RHA Collection of dermal fillers and the HintMD platform. Founded in 1999 and headquartered in Newark, California, Revance Therapeutics was previously known as Essentia Biosystems.
Private Equity Round in 2011
BioCritica is a biotechnology company dedicated to addressing critical care needs in the hospital market, particularly focusing on severe sepsis treatment with its product, Xigris. The company is actively developing a pipeline of additional products aimed at enhancing patient outcomes and supporting clinicians. BioCritica's mission centers on creating and commercializing innovative solutions that significantly improve the quality of life for patients facing critical health challenges.
Artisan Pharma, Inc., a biopharmaceutical company, provides critical-care and hospital-based therapeutics to patients, treating physicians, and payors in the United States and internationally. It offers ART-123, a novel, recombinant, and soluble thrombomodulin for the treatment of disseminated intravascular coagulation in sepsis. The company offers its products in Japan, China, Taiwan, and Korea. It has a strategic manufacturing alliance with A-Bio Pharma Pte Ltd. Artisan Pharma, Inc. was formerly known as Artisan Therapeutics, Inc. and changed its name to Artisan Pharma, Inc. in September 2006. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.
Protemix is a biopharmaceutical company that discovers, develops, and commercializes drug therapies for the prevention and treatment of cardiovascular disease, diabetes, and other metabolic disorders. The company was founded in 1999 and is based in Auckland, New Zealand with an additional office in San Diego, California.
Artisan Pharma, Inc., a biopharmaceutical company, provides critical-care and hospital-based therapeutics to patients, treating physicians, and payors in the United States and internationally. It offers ART-123, a novel, recombinant, and soluble thrombomodulin for the treatment of disseminated intravascular coagulation in sepsis. The company offers its products in Japan, China, Taiwan, and Korea. It has a strategic manufacturing alliance with A-Bio Pharma Pte Ltd. Artisan Pharma, Inc. was formerly known as Artisan Therapeutics, Inc. and changed its name to Artisan Pharma, Inc. in September 2006. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.